PARP1 and ovarian cancer: In addition, there are targeted radiotherapy and immunotherapy; advances have been made in the clinical treatment of ovarian cancer with bevacizumab (a recombinant human monoclonal IgG1 antibody that acts by inhibiting the biological activity of human vascular endothelial growth factor) or the poly ADP-ribose polymerase (PARP) inhibitor olaparib [3].